MAM
AKRO

Meeder Asset Management’s Akero Therapeutics AKRO Stock Holding History

Meeder Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,451
Closed -$44K – 1849
2020
Q3 		$44K Buy
+1,451
New +$50.7K ﹤0.01% 979

Other funds holding AKRO

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Meeder Asset Management's AKRO Position: Q4 2020 in Review

Meeder Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2020, closing a stake of 1,451 shares — an estimated $44K sold.

Meeder Asset Management first reported a position in AKRO in Q3 2020 and held it in 1 quarter. The position peaked at $44K in Q3 2020. 94 funds tracked by Wall St. Rank hold AKRO as of Q4 2020.

  • Meeder Asset Management reported no remaining Akero Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Meeder Asset Management sold 1,451 Akero Therapeutics shares in Q4 2020, an estimated $44K.
  • Meeder Asset Management first reported a position in Akero Therapeutics in Q3 2020 and held it in 1 quarter.
  • Meeder Asset Management's Akero Therapeutics position peaked at $44K in Q3 2020.
  • 94 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2020.

Based on Meeder Asset Management's 13F filing for Q4 2020, filed 9 Feb 2021.